NCCN affirms Avastin in breast cancer

The National Comprehensive Cancer Network updated its breast cancer guidelines to affirm its recommendation for Avastin bevacizumab as an option for metastatic breast cancer in combination with paclitaxel. However, NCCN did include a footnote to state that trials of Avastin plus chemotherapy in the first- or second-line setting have shown that Avastin "modestly improves time to progression and response rate but does not improve overall survival." Genentech Inc., a unit of Roche (SIX:ROG; OTCQX:RHHBY), markets Avastin in the U.S. Roche markets it elsewhere. ...